Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborator: Scios, Inc.
• Treatments: Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

• Decompensated heart failure hospitalization with at least 1 symptom and 1 sign of elevated filling pressures

• Admission estimated creatinine clearance =< 50 cc/min.

Exclusion Criteria:

• Systolic blood pressure < 85 mm Hg

• Cardiogenic shock

• Volume depletion

• Myocardial infarction, unstable angina within last 30 days

• Significant valvular stenosis, hypertrophic/restrictive cardiomyopathy, or constrictive pericarditis

• Chronic hemodialysis

• Anticipated major procedure during hospitalization i.e. left heart catheterization, surgery, or transplantation

• Enrolled in another research protocol within last 30 days.